In 1891, a New York surgeon named William Coley noticed an impossible pattern: his patients' terminal tumors completely vanished right after they caught severe bacterial infections.
Cancer cells are stealthy. Because they are mutated versions of a patient’s own tissue, they often fly under the radar of the immune system. Tumors actively suppress immune responses in their immediate vicinity by releasing chemical signals that tell patrolling T cells to power down. The tumor creates a localized "cold zone" where the body's natural defenses are blindfolded.
A severe infection acts as an alarm bell that temporarily shatters this stealth. When a virulent pathogen like Streptococcus enters the body, the immune system launches a systemic inflammatory response. This causes a surge in cytokines—proteins that act as emergency flares for the immune system.
This hyper-stimulated state overrides the tumor's localized suppressive signals. As armies of dendritic cells and T cells flood the body to hunt the bacterial invaders, they also infiltrate the tumor microenvironment. In the chaos of this heightened alert state, the blindfolds come off. The newly aggressive immune cells finally recognize the mutated proteins on the surface of the cancer cells as foreign threats and begin systematically destroying them alongside the infection.
William Coley tried to harness this mechanism by injecting cancer patients with dead bacteria, a mixture that became known as "Coley's Toxins." While the treatment was inconsistent and eventually eclipsed by the development of radiation and chemotherapy, the underlying principle was sound.
Today, this exact mechanism is a cornerstone of modern oncology. One of the standard treatments for early-stage bladder cancer does not involve chemotherapy drugs at all. Instead, doctors inject the BCG vaccine—a weakened form of the bacteria that causes tuberculosis—directly into the bladder. The resulting localized infection provokes an intense immune response that inadvertently sweeps up and destroys the surrounding cancer cells.